Reply to the Editor  by Ganesh, J. Saravana et al.
Although this study summarizes an ini-
tial experience, we thank the authors for
sharing with us their results and for their
contribution to this important new field of
interventional therapy.
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Reply to the Editor:
We appreciate the authors’ concerns about
the quality of ourwork published the Journal
of Thoracic and Cardiovascular Surgery.
We totally agree with the two underlined
points and we would like to simply answer
the two questions.
It is true that prosthesis sizing is an
important issue. All the reported patients
had an aortic annulus diameter ranging
from 20 to 23 mm. Smaller and larger annuli
were considered as contraindicated so as to
allow correct anchorage of the prosthesis
in the annulus.
All the patients had the echographic
aspect of a tricuspid aortic valve. We can-
not answer Zegdi and colleagues because
we do not have any experience with per-
cutaneous aortic valve implantation in
bicuspid valves. Bicuspid valves are gen-
erally more calcified than tricuspid valves
and frequently come with a moderate
dilatation of the aorta. They are less
favourable for currently used percutaneous
aortic valves.
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Does the method of lung
preservation influence outcome
after transplantation? An
analysis of 681 consecutive
procedures
To the Editor:
We read with great interest the study by Ga-
nesh and colleagues1 that compared various
graft preservation methods in lung trans-
plantation. The authors rigorously assessed
the association between the lung preserva-
tion method and the posttransplant survival
up to 3 years in a large cohort of patients;
they failed to detect any association. How-
ever, we think that the way the graft ische-
mic time was calculated and included in
the analysis may have biased the results.
Graft ischemic time has been shown to be
associated with survival after lung trans-
plantation in several studies.2,3 In these
studies, in case of double-lung transplanta-
tion, graft ischemic time was defined as
the time from donor crossclamping to reper-
fusion of the second lung. In their study, Ga-
nesh and colleagues considered ischemic
time as the time from donor crossclamping
to reperfusion of the first lung only. This
could lead to incorrect adjustment. Second,
we have found that the relationship between
graft ischemic time and survival could be of
exponential form, the graft ischemic time al-
tering the survival of recipients only when it
exceeds 4 to 6 hours.3 Unfortunately, the au-
thors did not report on the distribution of
graft ischemic time by the preservation
method. Given the incidence of local donors
in their cohort, we suspect that graft ische-
mic time was rather short in most patients.
This point is essential, because the efficacy
of different graft preservation solutions may
prove similar for short graft ischemic times
and different for longer ischemic times.
We think that the analysis of adjusted sur-
vival by preservation solution for patients
with a long ischemic time would have
yielded more insight in the efficacy of pres-
ervation solutions. However, the number of
patients in each group would have probably
been low, precluding powerful statistical
analysis. The authors report no interaction
between the graft ischemic time and the
preservation solution used; however, inter-
action testing is not powerful enough. We
agree that the way to definitely answer this
question is to conduct a randomized con-
trolled trial, and we think that such a trial
should stratify patients by the expected graft
ischemic time or the surgical procedure (sin-
gle vs bilateral lung transplantation).
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We appreciate the comments made by Tha-
but and colleagues on our article on lung
preservation.1 We agree that graft ischemia
time may be an important predictor to sur-
vival after lung transplantation, particularly
if this is particularly prolonged. The study
by Novick and colleagues2 did not find
any influence of graft ischemia time alone
on survival, but there was a significant
Letters to the EditorFigure 1. The distribution of ischemic times ac-
cording to preservation type. The line inserted in
each histogram is set at 330 minutes of ischemia.influence when associated with extremes of
donor age. Similarly, the study by the au-
thors themselves3 found graft ischemia
time to be significant only when it exceeded
330 minutes (5.5 hours). Thabut and col-
leagues are correct in assuming that the me-
dian graft ischemia time may be rather short
in our study, reflecting the local use of donor
organs. Of 336 bilateral lung transplants in
our study, only 27% (93/336) had graft is-
chemia times greater than 330 minutes.
Their distribution in the various preservation
groups is detailed in Figure 1 (with a line at
330 minutes). There were 38 (41%) each in
the Euro-Collins and low-potassium dextran
groups, 10 (11%) in the blood albumin
group, and 7 (7%) in the core cooling group.
Thus, if 51ˇ/2 hours is the current ‘‘safe’’ du-
ration of lung preservation, this is the likely
reason why our study did not show an effect
of ischemia time on early or midterm sur-
vival. However, even this duration of ische-
mia is injurious, as evidenced by the
association with rejection.
Our study involves a multicenter cohort
in which some centers perform bilaterallung transplantation using cardiopulmonary
bypass leading to equivalent total graft is-
chemic times (but not necessarily equal
warm ischemic times). Others perform
such transplants without cardiopulmonary
bypass. In these, we would agree that analy-
sis of the second lung ischemic time would
be relevant and concede the importance of
this point. Unfortunately, our audit did not
previously have comprehensive data accrual
for this variable, and therefore for unifor-
mity, we had to include the time between re-
trieval and reperfusion of the first lung as the
graft ischemic time in our study. This was
explained in our methodology. The audit da-
taset has since been modified.
We do agree that a randomized trial with
adequate stratification of ischemia time and
transplant type would more fully address the
effect of ischemia time and preservation
technique on survival and graft function af-
ter lung transplantation.
J. Saravana Ganesh, FRCS
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